Immunovant, Inc. (IMVT)
Nasdaq: IMVT · Biological Products, (No Diagnostic Substances) · Durham, NC · filing with the SEC since 2019
Who owns Immunovant, Inc.
As filed with the SECHolders of 5% or more
2
Roivant Sciences Ltd. holds 55.9% of Common Stock, par value $0.0001 per share, as its SCHEDULE 13D/A filed Dec 12, 2025 says.
Directors and officers
13
report now, of 33 people on the record since 2019. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 2 named at left.
Holders of 5% or moreshare of the class, as filed
Roivant Sciences Ltd.
SCHEDULE 13D/A · filed Dec 12, 2025 · Common Stock, par value $0.0001 per share · 56.9% in Apr 21, 2025
Fmr LLC
SCHEDULE 13G/A · filed Nov 5, 2025 · COMMON STOCK · 10.1% in Mar 7, 2025
Deep Track Capital, LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 5.59% in Mar 26, 2025
What IMVT reports owning in othersstakes of 5% or more, and other ties
Immunovant, Inc. reports no stake in another company in the record.
Insider tradesForm 4
63sales
1purchases
11sales on a scheduled plan
9people selling
$16.6Msold, in dollars
$350Mbought, in dollars
Open-market trades on Form 4 from Nov 12, 2025 to Nov 12, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 12, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window10 of 34 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Fromkin Andrew J. | director | 4 | $8.0M | 2 | 0 | $0 |
| Stout Jay S | Chief Technology Officer | 16 | $2.4M | 0 | 0 | $0 |
| Gloria Melanie | Chief Operating Officer | 15 | $1.7M | 0 | 0 | $0 |
| Girao Tiago | Chief Financial Officer | 4 | $1.6M | 0 | 0 | $0 |
| Van Tuyl Christopher | Chief Legal Officer | 11 | $1.5M | 0 | 0 | $0 |
| Venker Eric | Chief Executive Officer | 4 | $600,000 | 0 | 0 | $0 |
| Pande Atul | director | 6 | $500,000 | 6 | 0 | $0 |
| Hughes Douglas J. | director | 2 | $300,000 | 2 | 0 | $0 |
| Susman Robert Graham | director | 1 | $100,000 | 1 | 0 | $0 |
| Roivant Sciences Ltd. | director | 0 | $0 | 0 | 1 | $350M |